New York 2025-2026 Regular Session

New York Assembly Bill A07746

Introduced
4/8/25  
Refer
4/8/25  

Caption

Requires prescription bottles containing opioids to have a label affixed concerning the addictive nature of the drug.

Companion Bills

No companion bills found.

Previously Filed As

NY S07562

Requires prescription drug containers be labeled with a description of the size, shape, color and imprint of the prescription drug it contains.

NY A3131

Requires labeling of over-the-counter and prescription drugs containing major food allergen or gluten-containing grain.

NY SB1986

Relating to warning labels for opioid prescription drugs.

NY A08948

Relates to the distribution of educational materials regarding the misuse of and addiction to prescription drugs in counties with the most prevalent prescription substance use disorder.

NY S08285

Requires manufacturers of kratom products within the state to have a warning label that the product has not been approved by the federal food and drug administration and the products' side effects; prohibits labeling of kratom products as all natural.

NY A05852

Requires manufacturers of kratom products within the state to have a warning label that the product has not been approved by the federal food and drug administration and the products' side effects; prohibits labeling of kratom products as all natural.

NY S08827

Requires warning labels on addictive feature platforms which provide features such as addictive feeds, autoplay, infinite scroll, like counts, and/or push notifications; relates to the effectiveness of certain provisions of law relating thereto.

NY A09446

Requires warning labels on addictive feature platforms which provide features such as addictive feeds, autoplay, infinite scroll, like counts, and/or push notifications; relates to the effectiveness of certain provisions of law relating thereto.

NY HB2291

Opioids; containers; labeling; requirements; repeal

NY A08459

Clarifies that certain provisions related to statewide opioid settlement agreements shall cover settlements and releases related to any entities involved in the prescription drug marketing, supply and payment chain that may have contributed to the opioid epidemic through illegal conduct.

Similar Bills

No similar bills found.